Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay

International Journal of Cancer

Volumn 135, Issue 4, 2014, Pages 968-980

  Ingargiola, M ^a,b   Runge, R ^a,c   Heldt, J M ^a,b   Freudenberg, R ^a,c   Steinbach, J ^a,b   Cordes, N ^a,b,c   Baumann, M ^a,b,c   Kotzerke, J ^a,c   Brockhoff, G ^d   Kunz Schughart, L A ^a,b  

^a Institute of Radiooncology Helmholtz Zentrum Dresden Rossendorf ^*

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cetuximab; EGFR; tumor spheroids; Y 90

Indexed keywords

CETUXIMAB; CETUXIMAB Y 90; DIETHYLENE TRIAMINE PENTACETATE CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IRRADIATION; PRIORITY JOURNAL; PROTEIN BINDING; RADIATION DOSE; RADIOACTIVITY; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SPHEROID CELL; TREATMENT RESPONSE; TUMOR GROWTH; X RAY;

CETUXIMAB; EGFR; SPHEROID CONTROL DOSE 50% (SCD50); TUMOR SPHEROIDS; Y-90;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG CARRIERS; HEAD AND NECK NEOPLASMS; HUMANS; LIGANDS; MONTE CARLO METHOD; PROBABILITY; RADIATION TOLERANCE; RADIOIMMUNOTHERAPY; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; X-RAYS; YTTRIUM RADIOISOTOPES;

EID: 84902273154     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28735     Document Type: Article

References (59)

1. Pouget JP, Navarro-Teulon I, Bardies M, et al. Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol 2011; 8: 720-34.
2. Sharkey RM, Goldenberg DM,. Cancer radioimmunotherapy. Immunotherapy 2011; 3: 349-70.
3. Steiner M, Neri D,. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 2011; 17: 6406-16.
4. Goldenberg DM,. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43: 693-713.
5. Blumenthal RD, Sharkey RM, Haywood L, et al. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res 1992; 52: 6036-44.
6. Sharkey RM, Goldenberg DM,. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005; 46 (Suppl 1): 115S-27S.
7. Grandis JR, Tweardy DJ,. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-84.
8. Zimmermann M, Zouhair A, Azria D, et al. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 2006; 1: 1-6.
9. Milas L, Fan Z, Andratschke NH, et al. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004; 58: 966-71.
10. Baumann M, Krause M,. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004; 72: 257-66.
11. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23: 5560-7.
12. Mehra R, Cohen RB, Burtness BA,. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 2008; 6: 742-50.
13. Schmidt-Ullrich RK, Mikkelsen RB, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15: 1191-7.
14. Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10: 2493-506.
15. Bowers G, Reardon D, Hewitt T, et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 2001; 20: 1388-97.
16. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-37.
17. Nyati MK, Morgan MA, Feng FY, et al. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006; 6: 876-85.
18. Eke I, Schneider L, Forster C, et al. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells. Cancer Res 2013; 73: 297-306.
19. Bonner JA, Raisch KP, Trummell HQ, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 2000; 18: 47S-53S.
20. Huang SM, Bock JM, Harari PM,. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59: 1935-40.
21. Harari PM, Huang SM,. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427-33.
22. Meira DD, de Almeida VH, Mororo JS, et al. Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells. Br J Cancer 2009; 101: 782-91.
23. Gurtner K, Deuse Y, Butof R, et al. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 2011; 99: 323-30.
24. Krause M, Schutze C, Petersen C, et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother Oncol 2005a; 74: 109-15.
25. Frampton JE,. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs 2010; 70: 1987-2010.
26. Hirschhaeuser F, Menne H, Dittfeld C, et al. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010; 148: 3-15.
27. Kasten-Pisula U, Saker J, Eicheler W, et al. Cellular and tumor radiosensitivity is correlated to epidermal growth factor receptor protein expression level in tumors without EGFR amplification. Int J Radiat Oncol Biol Phys 2011; 80: 1181-8.
28. Eicheler W, Zips D, Dorfler A, et al. Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J Histochem Cytochem 2002; 50: 197-204.
29. Peickert S, Waurig J, Dittfeld C, et al. Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo. Lab Invest 2012; 92: 1607-22.
30. Ingargiola M, Dittfeld C, Runge R, et al. Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation. Cytometry A 2012; 81: 865-73.
31. Friedrich J, Seidel C, Ebner R, et al. Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009; 4: 309-24.
32. Maecker HT, Frey T, Nomura LE, et al. Selecting Fluorochrome Conjugates for Maximum Sensitivity. Cytometry Part A 2004: 169-73.
33. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005; 280: 31182-9.
34. Dittmann K, Mayer C, Fehrenbacher B, et al. Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654. FEBS Lett 2010; 584: 3878-84.
35. Lin TY, Chang JT, Wang HM, et al. Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78: 246-56.
36. Fan KH, Lin CY, Kang CJ, et al. Combined-modality treatment for advanced oral tongue squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007; 67: 453-61.
37. Rades D, Wolff C, Nadrowitz R, et al. Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 1226-31.
38. Baumann M, Krause M, Hill R,. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8: 545-54.
39. Yaromina A, Krause M, Thames H, et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 2007; 83: 304-10.
40. Hjelstuen MH, Rasch-Halvorsen K, Brekken C, et al. Penetration and binding of monoclonal antibody in human osteosarcoma multicell spheroids. Comparison of confocal laser scanning microscopy and autoradiography. Acta Oncol 1996; 35: 273-9.
41. Hoffmann TK, Schirlau K, Sonkoly E, et al. A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer 2009; 124: 2589-96.
42. Olabiran Y, Ledermann JA, Marston NJ, et al. The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies. Br J Cancer 1994; 69: 247-52.
43. Lee CM, Tannock IF,. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 2010; 10: 1-11.
44. Boswell CA, Tesar DB, Mukhyala K, et al. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010; 21: 2153-63.
45. Kwok CS, Crivici A, MacGregor WD, et al. Optimization of radioimmunotherapy using human malignant melanoma multicell spheroids as a model. Cancer Res 1989; 49: 3276-81.
46. Chen FM, Liu CZ, Epstein AL,. Effects of 131I-labeled TNT-1 radioimmunotherapy on HT-29 human colon adenocarcinoma spheroids. Cancer Immunol Immunother 1991; 33: 158-64.
47. Nordberg E, Friedman M, Gostring L, et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 2007; 34: 609-18.
48. Sorkin A, Goh LK,. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2009; 315: 683-96.
49. Oehme L, Dorr W, Wust P, et al. [Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry]. Nuklearmedizin 2008; 47: 205-9.
50. Fowler JF,. 21 years of biologically effective dose. Br J Radiol 2010; 83: 554-68.
51. Cremonesi M, Botta F, Di Dia A, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging 2010; 54: 37-51.
52. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8.
53. Bodei L, Cremonesi M, Grana CM, et al. Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging 2012; 39 (Suppl 1): S93-102.
54. Antczak C, Jaggi JS, LeFave CV, et al. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjug Chem 2006; 17: 1551-60.
55. Tabrizi MA, Roskos LK,. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007; 12: 540-7.
56. EMEA EMA. Scientific Discussion for the Approval of Erbitux, 2004: 1-47.
57. Vrana NE, Lavalle P, Dokmeci MR, et al. Engineering functional epithelium for regenerative medicine and in vitro organ models: a review. Tissue Eng Part B Rev 2013; 19: 529-43.
58. Groeber F, Holeiter M, Hampel M, et al. Skin tissue engineering-in vivo and in vitro applications. Adv Drug Deliv Rev 2011; 63: 352-66.
59. Dirks NL, Nolting A, Kovar A, et al. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol 2008; 48: 267-78.